MKI67 and breast cancer: In the phase II MONALEESA-1 study on HR+/HER2-negative BC patients, a decrease in the expression of the cell proliferation marker Ki-67 was observed in the combination arm (letrozole with ribociclib) and single agent arm (letrozole alone) (235).